A randomized, placebo-controlled, double-blind, parallel design phase 2 dose ranging trial to assess the safety and efficacy of DA-8159 [udenafil] tablets in male subjects with erectile dysfunction.

Trial Profile

A randomized, placebo-controlled, double-blind, parallel design phase 2 dose ranging trial to assess the safety and efficacy of DA-8159 [udenafil] tablets in male subjects with erectile dysfunction.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Udenafil (Primary)
  • Indications Erectile dysfunction
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Dong-A Pharmaceutical
  • Most Recent Events

    • 21 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top